CRA consultants support claims on abandoned generic collaboration

Following an abandoned collaboration agreement between a complex peptide formulator and a generic manufacturer, CRA was retained to support an academic senior consultant in the ensuing arbitration. CRA’s team examined lost profit damages for the formulator, examining uptake and pricing of the specialty drug with an orphan drug indication. The matter ultimately settled.

Meet our team

Additional contributors